Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa

Table 1 Number and age of patients included in the analysis

Site and Country	Reference	Age (year)			ASAQ	AL	AQ	AQ + SP	AS + SP	AS	CQ + SP	DP	Total
Site and Country	Reference	Median	Mininum	Maximum	ASAQ	AL	AQ	AQ + SP	AS + SP	AS	CQ + SP	DP	Total
Burkina Faso	[9]	2.0	0.5	5	750								750
Cameroon	[7]	6.2	1.0	65	110	56							166
Gabon	[8]*	5.5	1.3	11	108		110						218
Madagascar	[9]	7.4	1.4	53	119	60							179
Mali, Boulouga	[7]	4.7	0.9	24	135	68							203
Mali, Bancoumana	[10]	3.0	0.6	56	252				249	252			753
Rwanda, Kicukiro	[11]*	3.3	1.0	5	74			74				75	223
Rwanda, Mashesha	[11]*	3.0	1.1	5	89			93				87	269
Rwanda, Rukara	[11]*	2.1	1.0	5	89			91				90	270
Senegal, Keur-Socé	[7]	9.0	1.0	15	264	128							392
Senegal, Mlomp	[11]*	5.0	0.9	64	160		160						320
Uganda, Apac	[13]*	1.8	0.5	47	174			183			185		542
Uganda, Jinja	[13]*	3.6	0.5	65	189			186			168		543
Uganda, Tororo	[13, 14]*	1.6	0.5	56	398	204		181			166		949
Zanzibar, Kivungue	[12]	2.5	0.5	7	148	149							297
Zanzibar, Micheweni	[12]	2.1	0.5	5	54	51							105
Total		3.0	0.5	65	3113	716	270	808	249	252	519	252	6179

Legend: * studies including grading of intensity AQ, amodiaquine; AL, artemether-lumefantrine; AS, artesunate; DP, dihydroartemisinin-piperaquine; CQ, chloroquine; SP, sulphadoxine-pyrimethamine.

ISSN: 1475-2875